Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 9
Submit an article Journal homepage
48
Views
14
CrossRef citations to date
0
Altmetric
Review

Gene therapy of gynaecological diseases

Anna Kanerva University of Helsinki, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Transplantation Laboratory and Haartman Institute, P.O. Box 63 (Haartmaninkatu 8, 00290 Helsinki), Biomedicum, Helsinki 00014, Finland +358 9 1912 5464; +358 9 1912 5465; [email protected]; Helsinki University Central Hospital, Department of Obstetrics and Gynecology, Finland; Helsinki University Central Hospital, Laboratory of Transplantation Pathology, HUSLAB, Finland; Helsinki University Central Hospital, Department of Oncology, Finland
,
Mari Raki University of Helsinki, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Transplantation Laboratory and Haartman Institute, P.O. Box 63 (Haartmaninkatu 8, 00290 Helsinki), Biomedicum, Helsinki 00014, Finland +358 9 1912 5464; +358 9 1912 5465; [email protected]; Helsinki University Central Hospital, Laboratory of Transplantation Pathology, HUSLAB, Finland; Helsinki University Central Hospital, Department of Oncology, Finland
&
Akseli Hemminki University of Helsinki, Cancer Gene Therapy Group, Molecular Cancer Biology Program, Transplantation Laboratory and Haartman Institute, P.O. Box 63 (Haartmaninkatu 8, 00290 Helsinki), Biomedicum, Helsinki 00014, Finland +358 9 1912 5464; +358 9 1912 5465; [email protected]; Helsinki University Central Hospital, Laboratory of Transplantation Pathology, HUSLAB, Finland; Helsinki University Central Hospital, Department of Oncology, Finland
Pages 1347-1361 | Published online: 29 Aug 2007

Bibliography

  • JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
  • PARKIN DM, BRAY F, FERLAY J, PISANI P: Global cancer statistics, 2002. CA Cancer J. Clin. (2005) 55(2):74-108.
  • KANERVA A, HEMMINKI A: Adenoviruses for treatment of cancer. Ann. Med. (2005) 37:33-43.
  • GLASGOW JN, EVERTS M, CURIEL DT: Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. (2006) 13(9):830-844.
  • DOUGLAS JT, ROGERS BE, ROSENFELD ME, MICHAEL SI, FENG M, CURIEL DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. (1996) 14(11):1574-1578.
  • WATKINS SJ, MESYANZHINOV VV, KUROCHKINA LP, HAWKINS RE: The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. (1997) 4(10):1004-1012.
  • PEREBOEV AV, ASIEDU CK, KAWAKAMI Y et al.: Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. (2002) 9(17):1189-1193.
  • HAKKARAINEN T, HEMMINKI A, PEREBOEV AV et al.: CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin. Cancer Res. (2003) 9(2):619-624.
  • KASHENTSEVA EA, SEKI T, CURIEL DT, DMITRIEV IP: Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res. (2002) 62(2):609-616.
  • DMITRIEV I, KRASNYKH V, MILLER CR et al.: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. (1998) 72(12):9706-9713.
  • VANDERKWAAK TJ, WANG M, GOMEZ-NAVARRO J et al.: An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. (1999) 74(2):227-234.
  • WICKHAM TJ, TZENG E, SHEARS LL II et al.: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. (1997) 71(11):8221-8229.
  • SHINOURA N, YOSHIDA Y, TSUNODA R et al.: Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. (1999) 59(14):3411-3416.
  • RANKI T, KANERVA A, RISTIMAKI A et al.: A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Δ24, for the treatment of advanced breast cancer. Gene Ther. (2007) 14(1):58-67.
  • RANKI T, SARKIOJA M, HAKKARAINEN T, VON SMITTEN K, KANERVA A, HEMMINKI A: Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int. J. Cancer (2007) 121(1):165-174.
  • KANGASNIEMI L, KIVILUOTO T, KANERVA A et al.: Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin. Cancer Res. (2006) 12(10):3137-3144.
  • GUSE K, DIAS JD, BAUERSCHMITZ GJ et al.: Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo. Gene. Ther. (2007) 14(11):902-911.
  • BELOUSOVA N, KOROKHOV N, KRENDELSHCHIKOVA V et al.: Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. (2003) 77(21):11367-11377.
  • KANERVA A, MIKHEEVA GV, KRASNYKH V et al.: Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. (2002) 8(1):275-280.
  • KANERVA A, WANG M, BAUERSCHMITZ GJ et al.: Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. (2002) 5(6):695-704.
  • SHAYAKHMETOV DM, LI ZY, NI S, LIEBER A: Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res. (2002) 62(4):1063-1068.
  • NI S, BERNT K, GAGGAR A, LI ZY, KIEM HP, LIEBER A: Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum. Gene Ther. (2005) 16(6):664-677.
  • LEHMUSVAARA S, RAUTSI O, HAKKARAINEN T, WAHIFORS J: Utility of cell-permeable peptides for enhancement of virus-mediated gene transfer to human tumor cells. Biotechniques (2006) 40(5):573-574, 576.
  • BULLER RE, RUNNEBAUM IB, KARLAN BY et al.: A Phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. (2002) 9(7):553-566.
  • HASENBURG A, TONG XW, ROJAS-MARTINEZ A et al.: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. (2000) 7(6):839-844.
  • RAPER SE, CHIRMULE N, LEE FS et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. (2003) 80(1-2):148-158.
  • CHUNG I, SCHWARTZ PE, CRYSTAL RG, PIZZORNO G, LEAVITT J, DEISSEROTH AB: Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther. (1999) 6(2):99-106.
  • CASADO E, NETTELBECK DM, GOMEZ-NAVARRO J et al.: Transcriptional targeting for ovarian cancer gene therapy. Gynecol. Oncol. (2001) 82(2):229-237.
  • BARKER SD, COOLIDGE CJ, KANERVA A et al.: The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J. Gene Med. (2003) 5(4):300-310.
  • KANERVA A, BAUERSCHMITZ GJ, YAMAMOTO M et al.: A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. (2004) 11(6):552-559.
  • BAO R, SELVAKUMARAN M, HAMILTON TC: Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol. Oncol. (2002) 84(2):228-234.
  • BARKER SD, DMITRIEV IP, NETTELBECK DM et al.: Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther. (2003) 10(14):1198-1204.
  • ZHU ZB, MAKHIJA SK, LU B et al.: Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. (2004) 11(4):256-262.
  • BREIDENBACH M, REIN DT, EVERTS M et al.: Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. (2005) 12(2):187-193.
  • SHAHIN MS, HUGHES JH, SOOD AK, BULLER RE: The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer (2000) 89(9):2006-2017.
  • SANTOSO JT, TANG DC, LANE SB et al.: Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. (1995) 59(2):171-178.
  • MUJOO K, MANEVAL DC, ANDERSON SC, GUTTERMAN JU: Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene (1996) 12(8):1617-1623.
  • KIM CK, CHOI EJ, CHOI SH, PARK JS, HAIDER KH, AHN WS: Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. Gynecol. Oncol. (2003) 90(2):265-272.
  • BULLER RE, SHAHIN MS, HOROWITZ JA et al.: Long term follow-up of patients with recurrent ovarian cancer after ad p53 gene replacement with SCH 58500. Cancer Gene Ther. (2002) 9(7):567-572.
  • WOLF JK, BODURKA DC, GANO JB et al.: A Phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol. Oncol. (2004) 94(2):442-448.
  • ZEIMET AG, MARTH C: Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. (2003) 4(7):415-422.
  • TAIT DL, OBERMILLER PS, REDLIN-FRAZIER S et al.: A Phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res. (1997) 3(11):1959-1968.
  • TAIT DL, OBERMILLER PS, HATMAKER AR, REDLIN-FRAZIER S, HOLT JT: Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. (1999) 5(7):1708-1714.
  • DESHANE J, LOECHEL F, CONRY RM, SIEGAL GP, KING CR, CURIEL DT: Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. (1994) 1(5):332-337.
  • DESHANE J, SIEGAL GP, ALVAREZ RD et al.: Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. (1995) 96(6):2980-2989.
  • SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
  • ALVAREZ RD, BARNES MN, GOMEZ-NAVARRO J et al.: A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a Phase I trial. Clin. Cancer Res. (2000) 6(8):3081-3087.
  • HORTOBAGYI GN, UENO NT, XIA W et al.: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a Phase I clinical trial. J. Clin. Oncol. (2001) 19(14):3422-3433.
  • MADHUSUDAN S, TAMIR A, BATES N et al.: A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. (2004) 10(9):2986-2996.
  • ROSENFELD ME, WANG M, SIEGAL GP et al.: Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med. (1996) 74(8):455-462.
  • ALVAREZ RD, GOMEZ-NAVARRO J, WANG M et al.: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol. Ther. (2000) 2(5):524-530.
  • HEMMINKI A, BELOUSOVA N, ZINN KR et al.: An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol. Ther. (2001) 4(3):223-231.
  • HEMMINKI A, ZINN KR, LIU B et al.: In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J. Natl. Cancer Inst. (2002) 94(10):741-749.
  • RAKI M, HAKKARAINEN T, BAUERSCHMITZ GJ et al.: Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther. (2007) [Epub ahead of print].
  • HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
  • ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
  • MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus IFN α in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
  • BOOCOCK CA, CHARNOCK-JONES DS, SHARKEY AM et al.: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. (1995) 87(7):506-516.
  • DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 255(5047):989-991.
  • MAHASRESHTI PJ, NAVARRO JG, KATARAM M et al.: Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin. Cancer Res. (2001) 7(7):2057-2066.
  • MAHASRESHTI PJ, KATARAM M, WANG MH et al.: Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res. (2003) 9(7):2701-2710.
  • MAHENDRA G, KUMAR S, ISAYEVA T et al.: Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther. (2005) 12(1):26-34.
  • ISAYEVA T, REN C, PONNAZHAGAN S: Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther. (2007) 14(2):138-146.
  • SUBRAMANIAN IV, BUI NGUYEN TM, TRUSKINOVSKY AM, TOLAR J, BLAZAR BR, RAMAKRISHNAN S: Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. (2006) 66(8):4319-4328.
  • INDRACCOLO S, TISATO V, TOSELLO V et al.: IFN-α gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum. Gene Ther. (2005) 16(8):957-970.
  • STERMAN DH, GILLESPIE CT, CARROLL RG et al.: IFN-β adenoviral gene therapy in a patient with ovarian cancer. Nat. Clin. Pract. Oncol. (2006) 3(11):633-639.
  • PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
  • JIANG M, SHI W, ZHANG Q et al.: Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin. Cancer Res. (2006) 12(20 Part 1):6179-6185.
  • PAGE JG, TIAN B, SCHWEIKART K et al.: Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a Phase I trial for recurrent ovarian cancer. Am. J. Obstet. Gynecol. (2007) 196(4):389.e1-9; discussion 389.e9-10.
  • XIA ZJ, CHANG JH, ZHANG L et al.: Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng (2004) 23(12):1666-1670.
  • PEARSON S, JIA H, KANDACHI K: China approves first gene therapy. Nat. Biotechnol. (2004) 22(1):3-4.
  • YU W, FANG H: Clinical trials with oncolytic adenovirus in china. Curr. Cancer Drug Targets (2007) 7(2):141-148.
  • BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373-376.
  • VASEY PA, SHULMAN LN, CAMPOS S et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene- deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. (2002) 20(6):1562-1569.
  • SUZUKI K, FUEYO J, KRASNYKH V, REYNOLDS PN, CURIEL DT, ALEMANY R: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. (2001) 7(1):120-126.
  • KANERVA A, ZINN KR, CHAUDHURI TR et al.: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. (2003) 8(3):449-458.
  • LAM JT, KANERVA A, BAUERSCHMITZ GJ et al.: Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J. Gene Med. (2004) 6(12):1333-1342.
  • BAUERSCHMITZ GJ, LAM JT, KANERVA A et al.: Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. (2002) 62(5):1266-1270.
  • LAM JT, HEMMINKI A, KANERVA A et al.: A three-dimensional assay for measurement of viral-induced oncolysis. Cancer Gene Ther. (2007) 14(4):421-430.
  • FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al.: A mutant oncolytic adenovirus targeting the rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19(1):2-12.
  • HEISE C, HERMISTON T, JOHNSON L et al.: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. (2000) 6(10):1134-1139.
  • HAMADA K, KOHNO S, IWAMOTO M et al.: Identification of the human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res. (2003) 63(10):2506-2512.
  • REIN DT, BREIDENBACH M, KIRBY TO et al.: A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. (2005) 11(3):1327-1335.
  • BAUERSCHMITZ GJ, GUSE K, KANERVA A et al.: Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol. Ther. (2006) 14(2):164-174.
  • RUSSELL SJ: RNA viruses as virotherapy agents. Cancer Gene Ther. (2002) 9(12):961-966.
  • LIU TC, GALANIS E, KIRN D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. (2007) 4(2):101-117.
  • KANERVA A, ZINN KR, PENG KW et al.: Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther. (2005) 12(1):87-94.
  • RAJECKI M, KANERVA A, STENMAN UH et al.: Treatment of prostate cancer with Ad5/3Δ24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol. Cancer Ther. (2007) 6(2):742-751.
  • ZUR HAUSEN H: Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer (2002) 2(5):342-350.
  • CARSON A, WANG Z, XIAO X, KHAN SA: A DNA recombination-based approach to eliminate papillomavirus infection. Gene Ther. (2005) 12(6):534-540.
  • NI S, GAGGAR A, DI PAOLO N et al.: Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther. (2006) 13(12):1072-1081.
  • BAUERSCHMITZ GJ, KANERVA A, WANG M et al.: Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int. J. Cancer (2004) 111(2):303-309.
  • BALAGUE C, NOYA F, ALEMANY R, CHOW LT, CURIEL DT: Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J. Virol. (2001) 75(16):7602-7611.
  • HEIDEMAN DA, STEENBERGEN RD, VAN DER TORRE J et al.: Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. Mol. Ther. (2005) 12(6):1083-1090.
  • DAS S, EL-DEIRY WS, SOMASUNDARAM K: Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73β. Oncogene (2003) 22(52):8394-8402.
  • HAMADA K, SHIRAKAWA T, GOTOH A, ROTH JA, FOLLEN M: Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer. Gynecol. Oncol. (2006) 103(3):820-830.
  • LIU M, ACRES B, BALLOUL JM et al.: Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA (2004) 101 (Suppl. 2):14567-14571.
  • SMITH RR, HUEBNER RJ, ROWE WP, SCHATTEN WE, THOMAS LBT, LB: Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1956) 9(6):1211-1218.
  • BOYD J: Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes. Gynecol. Oncol. (1996) 61(2):163-165.
  • RAMONDETTA L, MILLS GB, BURKE TW, WOLF JK: Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin. Cancer Res. (2000) 6(1):278-284.
  • GRUNDKER C, HUSCHMAND NIA A, EMONS G: Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol. Cancer Ther. (2005) 4(2):225-231.
  • Edmonds K: Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates. Blackwell Science Ltd, Oxford, UK (1999).
  • NIU H, SIMARI RD, ZIMMERMANN EM, CHRISTMAN GM: Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet. Gynecol. (1998) 91(5 Part 1):735-740.
  • AL-HENDY A, LEE EJ, WANG HQ, COPLAND JA: Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am. J. Obstet. Gynecol. (2004) 191(5):1621-1631.
  • HEAPS JM, NIEBERG RK, BEREK JS: Malignant neoplasms arising in endometriosis. Obstet. Gynecol. (1990) 75(6):1023-1028.
  • DABROSIN C, GYORFFY S, MARGETTS P, ROSS C, GAULDIE J: Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am. J. Pathol. (2002) 161(3):909-918.
  • FORTIN M, LEPINE M, MERLEN Y et al.: Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. Mol. Ther. (2004) 9(4):540-547.
  • LEVINE RJ, MAYNARD SE, QIAN C et al.: Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. (2004) 350(7):672-683.
  • SENUT MC, SUHR ST, GAGE FH: Gene transfer to the rodent placenta in situ. A new strategy for delivering gene products to the fetus. J. Clin. Invest. (1998) 101(8):1565-1571.
  • HEIKKILA A, HILTUNEN MO, TURUNEN MP et al.: Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes. Gene Ther. (2001) 8(10):784-788.
  • MILLER AG, APLIN JD, WESTWOOD M: Adenovirally mediated expression of insulin-like growth factors enhances the function of first trimester placental fibroblasts. J. Clin. Endocrinol. Metab. (2005) 90(1):379-385.
  • EUN KWON H, TAYLOR HS: The role of HOX genes in human implantation. Ann. NY Acad. Sci. (2004) 1034:1-18.
  • BAGOT CN, TROY PJ, TAYLOR HS: Alteration of maternal Hoxa10 expression by in vivo gene transfection affects implantation. Gene Ther. (2000) 7(16):1378-1384.
  • IMMONEN A, VAPALAHTI M, TYYNELA K et al.: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. (2004) 10(5):967-972.
  • PUUMALAINEN AM, VAPALAHTI M, AGRAWAL RS et al.: β-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. (1998) 9(12):1769-1774.
  • LE LP, LE HN, DMITRIEV IP et al.: Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J. Natl. Cancer Inst. (2006) 98(3):203-214.
  • PENG KW, FACTEAU S, WEGMAN T, O'KANE D, RUSSELL SJ: Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat. Med. (2002) 8(5):527-531.
  • GLASGOW JN, BAUERSCHMITZ GJ, CURIEL DT, HEMMINKI A: Transductional and transcriptional targeting of adenovirus for clinical applications. Curr. Gene Ther. (2004) 4(1):1-14.
  • HERMISTON TW, KUHN I: Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther. (2002) 9(12):1022-1035.
  • KHURI FR, NEMUNAITIS J, GANLY I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. (2000) 6(8):879-885.
  • RAKI M, KANERVA A, RISTIMAKI A et al.: Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. (2005) 12:1198-1205.
  • MASTRANGELI A, HARVEY BG, YAO J et al.: “Sero-switch” adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. (1996) 7(1):79-87.
  • CHRIST M, LUSKY M, STOECKEL F et al.: Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. (1997) 57(1-3):19-25.
  • CHEN Y, YU DC, CHARLTON D, HENDERSON DR: Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. (2000) 11(11):1553-1567.
  • HEMMINKI A, KELLOKUMPU-LEHTINEN PL: Harmful impact of EU clinical trials directive. BMJ (2006) 332(7540):501-502.
  • KAY MA, MANNO CS, RAGNI MV et al.: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. (2000) 24(3):257-261.
  • HACEIN-BEY-ABINA S, LE DEIST F, CARLIER F et al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. (2002) 346(16):1185-1193.
  • YLA-HERTTUALA S, ALITALO K: Gene transfer as a tool to induce therapeutic vascular growth. Nat. Med. (2003) 9(6):694-701.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.